Ruthenium(II) complexes as bioorthogonal two-photon photosensitizers for tumour-specific photodynamic therapy against triple-negative breast cancer cells

Mingwei Lin; Shanshan Zou; Xinxing Liao; Yu Chen; Diqing Luo; Liangnian Ji; Hui Chao

doi:10.1039/d1cc00661d

Ruthenium(II) complexes as bioorthogonal two-photon photosensitizers for tumour-specific photodynamic therapy against triple-negative breast cancer cells

Chem Commun (Camb). 2021 May 4;57(36):4408-4411. doi: 10.1039/d1cc00661d.

Authors

Mingwei Lin¹, Shanshan Zou¹, Xinxing Liao¹, Yu Chen¹, Diqing Luo², Liangnian Ji¹, Hui Chao¹

Affiliations

¹ MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou, 510275, P. R. China. ceschh@mail.sysu.edu.cn chenyu63@mail.sysu.edu.cn.
² Department of Dermatology, The Eastern Division of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510275, P. R. China. luodq@mail.sysu.edu.cn.

PMID: 33949487
DOI: 10.1039/d1cc00661d

Abstract

Herein, we developed the first Ru(ii) complex-based bioorthogonal two-photon photosensitizers. Through bioorthogonal labelling, they realize effective tumour-specific photodynamic therapy against triple-negative breast cancer cells.

MeSH terms

Antineoplastic Agents / chemical synthesis
Antineoplastic Agents / chemistry
Antineoplastic Agents / pharmacology*
Cell Proliferation / drug effects
Coordination Complexes / chemical synthesis
Coordination Complexes / chemistry
Coordination Complexes / pharmacology*
Drug Screening Assays, Antitumor
Female
Humans
Photochemotherapy*
Photons*
Photosensitizing Agents / chemical synthesis
Photosensitizing Agents / chemistry
Photosensitizing Agents / pharmacology*
Ruthenium / chemistry
Ruthenium / pharmacology*
Triple Negative Breast Neoplasms / drug therapy*
Triple Negative Breast Neoplasms / pathology

Substances

Antineoplastic Agents
Coordination Complexes
Photosensitizing Agents
Ruthenium